| Dr Jason Murray Sullivan, MD | |
|
668 Skyline Dr, Jackson, TN 38301-3951 | |
| (731) 424-2414 | |
| (731) 424-4444 |
| Full Name | Dr Jason Murray Sullivan |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 29 Years |
| Location | 668 Skyline Dr, Jackson, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528047586 | NPI | - | NPPES |
| 3838587 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | MD0031354 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jackson-madison County General Hospital | Jackson, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Skyline Eye Clinic, Pc | 0042253882 | 9 |
News Archive
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States.
Researchers at the RIKEN Center for Brain Science have discovered a mutation that can protect against Alzheimer's disease in mice. Published in the scientific journal Nature Communications, the study found that a specific mutation can reduce the characteristic accumulation of the amyloid-beta peptide that occurs.
Alectos Therapeutics Inc. today announced a research collaboration with Merck, headquartered in Whitehouse Station, N.J., to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target.
Humanin is a potential therapeutic agent for Alzheimer's disease, and its derivative, S14G-humanin, is 1 000-fold stronger in its neuroprotective effect against Alzheimer's disease-relevant insults. Al-though effective, the detailed molecular mechanism through which S14G-humanin exerts its effects remains unclear.
Oncolytics Biotech Inc. announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
› Verified 1 days ago
| Entity Name | Skyline Eye Clinic, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154328813 PECOS PAC ID: 0042253882 Enrollment ID: O20050602001098 |
News Archive
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States.
Researchers at the RIKEN Center for Brain Science have discovered a mutation that can protect against Alzheimer's disease in mice. Published in the scientific journal Nature Communications, the study found that a specific mutation can reduce the characteristic accumulation of the amyloid-beta peptide that occurs.
Alectos Therapeutics Inc. today announced a research collaboration with Merck, headquartered in Whitehouse Station, N.J., to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target.
Humanin is a potential therapeutic agent for Alzheimer's disease, and its derivative, S14G-humanin, is 1 000-fold stronger in its neuroprotective effect against Alzheimer's disease-relevant insults. Al-though effective, the detailed molecular mechanism through which S14G-humanin exerts its effects remains unclear.
Oncolytics Biotech Inc. announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Murray Sullivan, MD 668 Skyline Dr, Jackson, TN 38301-3951 Ph: (731) 424-2414 | Dr Jason Murray Sullivan, MD 668 Skyline Dr, Jackson, TN 38301-3951 Ph: (731) 424-2414 |
News Archive
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States.
Researchers at the RIKEN Center for Brain Science have discovered a mutation that can protect against Alzheimer's disease in mice. Published in the scientific journal Nature Communications, the study found that a specific mutation can reduce the characteristic accumulation of the amyloid-beta peptide that occurs.
Alectos Therapeutics Inc. today announced a research collaboration with Merck, headquartered in Whitehouse Station, N.J., to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target.
Humanin is a potential therapeutic agent for Alzheimer's disease, and its derivative, S14G-humanin, is 1 000-fold stronger in its neuroprotective effect against Alzheimer's disease-relevant insults. Al-though effective, the detailed molecular mechanism through which S14G-humanin exerts its effects remains unclear.
Oncolytics Biotech Inc. announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
› Verified 1 days ago
Stephen Dumas Hammond Jr., MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 668 Skyline Dr, Jackson, TN 38301 Phone: 731-424-2414 | |
Dr. William Bradford Priester, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 609 Skyline Dr, Jackson, TN 38301 Phone: 731-427-7799 Fax: 731-427-1476 | |
Dr. Mark Roy Bateman, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 668 Skyline Dr, Jackson, TN 38301 Phone: 731-424-2414 Fax: 731-424-4444 | |
Mrs. Hilary C. Grissom, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 668 Skyline Dr, Jackson, TN 38301 Phone: 731-424-2414 Fax: 731-424-4444 | |
James Alfred Price Jr., MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 668 Skyline Drive, Jackson, TN 38301 Phone: 731-424-2414 | |
Dr. Divya Lakshmi Indrakanti, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 112 Stonebridge Blvd, Jackson, TN 38305 Phone: 731-664-1994 | |
Laura L Dipuma, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2027 Greystone Sq, Jackson, TN 38305 Phone: 731-668-6882 Fax: 731-668-6882 |